p53 Protein in Colorectal Cancer and Its Prognostic Importance
Author Information
Author(s): A. Yamaguchi, G. Nakagawaral, Y. Kurosaka, G. Nishimura, Y. Yonemura, I. Miyazaki
Primary Institution: Kanazawa University
Hypothesis
Does p53 immunoreactivity correlate with prognosis in colorectal cancer?
Conclusion
p53 immunoreactivity may serve as a useful prognostic marker for colorectal cancers, with p53-positive tumors associated with poorer outcomes.
Supporting Evidence
- 59.6% of colorectal cancers showed p53 protein expression.
- Patients with p53-positive tumors had a 5-year survival rate of 58.1%.
- Patients with p53-negative tumors had a 5-year survival rate of 76.3%.
- p53-positive tumors were more frequently associated with liver metastasis.
Takeaway
This study found that many colorectal cancer patients have a protein called p53 that can help doctors predict how well they will do after treatment.
Methodology
The study analyzed p53 protein expression in 203 colorectal cancer biopsy specimens using immunohistochemistry.
Limitations
The study did not find significant correlations between p53 expression and several clinicopathological factors.
Participant Demographics
112 colon cancer patients and 91 rectal cancer patients.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website